ClinicalTrials.gg
CompletedNCT07302269Updated Nov 9, 2026

Study of the Safety, Tolerability, Pharmacokinetics of VV261 Tablets in Chinese Healthy Volunteers

A Phase 1 interventional study of VV261 5mg group and VV261 20mg Group in Healthy Volunteers, sponsored by Vigonvita Life Sciences. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Vigonvita Life Sciences · Phase 1, Interventional, and Treatment

Updated Nov 9, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This is a randomized, double-blind, placebo-controlled, single ascending-dose study to evaluate the safety, tolerability and pharmacokinetics characteristics of VV261 tablets in healthy adults.

Read the detailed description

The study is designed to enroll 58 volunteers. The pilot study is an open-labelled study where both volunteers receive 5 mg VV261 tablets. The formal study, conducted as a double-blind study, comprise 7dose groups with 8 volunteers (both sexes) each. Volunteers will be randomly assigned to receive either the VV261 tablets or placebo in a ratio of 6:2. The formal study's dose groups are designed as 20 mg, 50 mg, 150 mg, 300 mg, 500 mg, 750 mg, and 1000 mg. Based on observed tolerability and safety data or obtained pharmacokinetic data, adjustments are allowed at all dose levels in the clinical trial.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • VV261
  • Phase I
  • Tolerability
  • Pharmacokinetic
  • Safety
03

In context

Lead sponsor

Vigonvita Life Sciences is the lead sponsor of 39 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18 to 45 years old, males or females;
  2. Males weight no less than 50 kg, females weight no less than 45 kg, with of 19 to 26 kg/m\^2;
  3. Vital signs examination, physical examination, laboratory examination , examination chest CT and B-ultrasound of liver, gallbladder, pancreas, spleen, kidney and thyroid results are normal or considered abnormal without clinical significance by the investigator;
  4. Volunteers who are willing to take proper methods during the study and within 3 months after the the last administration;
  5. Volunteers who are able to understand and follow the study protocol and instructions; volunteers who have voluntarily decided to participate in this study, and sign the form.

Exclusion criteria

Exclusion Criteria:

  1. Volunteers with to preparation or any of the ;
  2. Volunteers with allergic constitution (such as asthma, urticaria, eczematous dermatitis and other allergic diseases), or have a history of drug or food allergy;
  3. Volunteers with central nervous system, cardiovascular system, gastrointestinal, respiratory system, urinary, hematologic, or metabolic disorders that require medical intervention or other diseases (such as psychiatric history) that are not suitable for clinical trials;Volunteers with a history of gastrointestinal conditions that may impair drug absorption (e.g., gastrectomy or small intestine resection, atrophic gastritis, gastrointestinal ulcers or perforations/fistulas, gastrointestinal bleeding, or obstruction);
  4. Volunteers with a history of diseases affecting bone marrow hematopoietic function or reducing immunological function (including leukemia, myelodysplastic syndrome, aplastic anemia, systemic lupus erythematosus, rheumatoid arthritis, etc.) or treatment history (tumor chemotherapy or radiotherapy, use of , etc.);
  5. Volunteers with a history of spleen diseases;
  6. If any of the following parameters were considered abnormal with clinical significance: white blood cell count, red blood cell count, count, reticulocyte count, and ;
  7. If any of the following parameters were considered abnormal with clinical significance: total , alkaline phosphatase, , and aspartate aminotransferase;
  8. Volunteers who have received blood transfusion or used blood products within 3 months before screening or who have lost more than ≥400 mL of blood due to other reasons (excluding menstruation);
  9. Volunteers who have participated in clinical trials and received drugs within 3 months before screening;
  10. Volunteers who have taken any prescription drugs, over-the-counter drugs, Chinese herbal medicines or health products within 2 weeks before screening;
  11. Volunteers who have received vaccination within the first 2 weeks before screening, or planned to receive any vaccine during the trial or within 1 week after the end of the study;
  12. Volunteers with a history of drug abuse within 1 year before screening or positive urine drug screening within 1 year before screening results (morphine, tetrahydrocannabinol, methamphetamine, dimethylene diphenazine , ketamine, and cocaine);
  13. Volunteers who drink more than 14 standard units or at least twice a day per week within one year before screening,(one standard unit equals 200 mL of beer with 5% alcohol or 25 mL of white wine with 40% alcohol content or 85 mL of red wine with 12% alcohol);
  14. Volunteers who smok more than 5 cigarettes a day within one year before screening;
  15. Volunteers who can't quit smoking or drinking during the trial period;
  16. Volunteers who are positive for virus surface antigen, virus antibody, treponema pallidum antibody or antibody (Anti-HIV);
  17. Volunteers who cannot tolerate blood collection with intravenous indwelling needles or blood fainting;
  18. Volunteers with lactose intolerance or cannot comply with a uniform diet (such as special dietary requirements, intolerance of standard meals, etc.), volunteers who have consumed excessive amounts of strong tea, coffee or caffeinated beverages in the 3 months before screening;
  19. Volunteers with difficulty in swallowing tablets;
  20. Pregnant or lactating women or male volunteers whose female partners plan to conceive within 3 months;
  21. The investigator believes that there are other unsuitable factors to participate this trial.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    VV261

    Drug: VV261 5mg group · Drug: VV261 20mg Group · Drug: VV261 50mg group · Drug: VV261 100mg group · Drug: VV261 150mg group · Drug: VV261 300mg group · Drug: VV261 500mg group · Drug: VV261 750mg group · Drug: VV261 1000mg group

  • Placebo comparator
    Placebo

    Drug: VV261 20mg Group · Drug: VV261 50mg group · Drug: VV261 100mg group · Drug: VV261 150mg group · Drug: VV261 300mg group · Drug: VV261 500mg group · Drug: VV261 750mg group · Drug: VV261 1000mg group

Interventions

  • DrugVV261 5mg group

    2 subjects will receive VV261 5mg, orally

  • DrugVV261 20mg Group

    6 subjects receive VV261 20mg,orally; 2 subjects will receive placebo,orally.

  • DrugVV261 50mg group

    6 subjects receive VV261 50mg,orally; 2 subjects will receive placebo,orally.

  • DrugVV261 100mg group

    6 subjects receive VV261 100mg,orally; 2 subjects will receive placebo,orally.

  • DrugVV261 150mg group

    6 subjects receive VV261 150mg,orally; 2 subjects will receive placebo,orally.

  • DrugVV261 300mg group

    6 subjects receive VV261 300mg,orally; 2 subjects will receive placebo,orally.

  • DrugVV261 500mg group

    6 subjects receive VV261 500mg,orally; 2 subjects will receive placebo,orally.

  • DrugVV261 750mg group

    6 subjects receive VV261 750mg,orally; 2 subjects will receive placebo,orally.

  • DrugVV261 1000mg group

    6 subjects receive VV261 1000mg,orally; 2 subjects will receive placebo,orally.

06

What researchers measure

Primary outcomes

  1. Cmax

    maximum observed plasma concentration

    Time frame: 48 hours after administration]

  2. AUC0-t

    area under the plasma concentration time curve from time zero to the last measurable concentration

    Time frame: 48 hours after administration

  3. AUC0-∞

    area under the plasma concentration-time curve from time zero to infinity

    Time frame: 48 hours after administration]

  4. Tmax

    time at which Cmax occurs

    Time frame: 48 hours after administration

  5. t1/2

    half life of elimination

    Time frame: 48 hours after administration

  6. Kel

    elimination rate constant

    Time frame: 48 hours after administration

  7. CLz/F

    apparent clearance

    Time frame: 48 hours after administration

  8. Vd/F

    apparent volume of distribution during the terminal phase

    Time frame: 48 hours after administration

  9. MRT

    mean residence time

    Time frame: 48 hours after administration

  10. AE & SAE

    Adverse event \& serious adverse events

    Time frame: from day1 to day7 after administration

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jan 2026 to primary completion in Aug 2026, 7 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: primary completion Jun 2026 → Aug 2026 and completion Jun 2026 → Aug 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2025
First posted
Dec 24, 2025
StartActual
Jan 4, 2026
Primary completionActual
Aug 19, 2026was Jun 2026
CompletionActual
Aug 19, 2026was Jun 2026
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 9, 2026
Primary completion
Jun 30, 2026→Aug 19, 2026 (actual)
Nov 9, 2026
Study completion
Jun 30, 2026→Aug 19, 2026 (actual)
Nov 9, 2026
Enrollment
58 (estimated)→66 (actual)
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Recruiting→Completed
    Primary completion Jun 30, 2026→Aug 19, 2026 (now actual)
    Study completion Jun 30, 2026→Aug 19, 2026 (now actual)
    Enrollment 58 (estimated)→66 (actual)
    + 2 other changes: contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07302269
Responsible party
Sponsor
First posted
Dec 24, 2025
Start date
Jan 4, 2026
Primary completion
Aug 19, 2026
Completion
Aug 19, 2026
Last update
Nov 9, 2026

Study contacts

Huan Zhou
principal investigator · The First Affiliated Hospital of Anhui Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion